Provided by Tiger Trade Technology Pte. Ltd.

Akari Therapeutics PLC

0.2479
+0.01295.49%
Post-market: 0.24800.0000+0.02%19:37 EST
Volume:130.09K
Turnover:31.90K
Market Cap:11.35M
PE:-0.44
High:0.2600
Open:0.2460
Low:0.2262
Close:0.2350
52wk High:1.73
52wk Low:0.2178
Shares:45.78M
Float Shares:34.53M
Volume Ratio:0.68
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5691
EPS(LYR):-1.6570
ROE:-197.24%
ROA:-34.20%
PB:0.50
PE(LYR):-0.15

Loading ...

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

MT Newswires Live
·
9 hours ago

European Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading

MT Newswires Live
·
Feb 06

Akari Therapeutics to Present Next-Generation ADC Platform at Webull Financial Virtual Conference

Reuters
·
Feb 05

European Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading; Up for Week

MT Newswires Live
·
Jan 31

Akari Therapeutics files patent covering AKTX-102

TIPRANKS
·
Jan 26

Akari Therapeutics Files Patent Application for New ADC Candidate AKTX-102 Targeting CEACAM5 in Solid Tumors

Reuters
·
Jan 26

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Up 1.4% for Week

MT Newswires Live
·
Jan 24

Akari Therapeutics plc Announces Date for Upcoming Shareholder Meeting

Reuters
·
Jan 23

European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading

MT Newswires Live
·
Jan 16

BRIEF-Akari Therapeutics Releases CEO Corner Segment With CEO Abizer Gaslightwala

Reuters
·
Jan 09

Akari Therapeutics Highlights 2025 Progress and Plans Clinical Transition in 2026

Reuters
·
Jan 09

Akari Therapeutics to Present ADC Platform and Milestones at Biotech Showcase

Reuters
·
Jan 08

European Equities Traded in US as ADRs Rise in Tuesday Trading

MT Newswires Live
·
Jan 07

Akari Therapeutics Initiated at Buy by Ladenburg Thalmann

Dow Jones
·
Jan 05

Ladenburg Thalmann Initiates Akari Therapeutics at Buy

MT Newswires Live
·
Jan 05

Akari Therapeutics Partners with WuXi XDC to Advance ADC Candidate Toward Clinical Trials

Reuters
·
Dec 30, 2025

WuXi XDC Selected to Manufacture Akari Therapeutics' AKTX-101 for Phase 1 Clinical Trial

Reuters
·
Dec 23, 2025

Akari Therapeutics Initiates Gmp Manufacturing of Aktx-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial

THOMSON REUTERS
·
Dec 23, 2025

Akari Therapeutics Plc : Maxim Group Cuts Target Price to $2 From $5

THOMSON REUTERS
·
Dec 22, 2025

U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart

Reuters
·
Dec 22, 2025